For the quarter ending 2026-03-31, DCOY has $8,423,275 in assets. $4,545,890 in debts. $7,820,608 in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | ||
|---|---|---|---|---|
| Cash, cash equivalents, and restricted cash | 7,820,608 | 10,709,937 | ||
| Prepaid expenses and other current assets | 537,044 | 275,223 | ||
| Total current assets | 8,357,652 | 10,985,160 | ||
| Property and equipment, net | 35,741 | 40,559 | ||
| Other assets | 29,882 | 30,988 | ||
| Total assets | 8,423,275 | 11,056,707 | ||
| Accounts payable | 936,030 | 940,586 | ||
| Accrued expenses and other current liabilities | 244,456 | 859,442 | ||
| Deferred revenue | 3,225,581 | 3,225,581 | ||
| Notes payable | - | 0 | ||
| Due to related parties | 139,823 | 139,823 | ||
| Other current liability | - | 2,306 | ||
| Total current liabilities | 4,545,890 | 5,167,738 | ||
| Total liabilities | 4,545,890 | 5,167,738 | ||
| Common stock, 0.0001 par value100,000,000 shares authorized 531,968 and 8,006 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 53 | 53 | ||
| Additional paid-in capital | 100,544,058 | 100,331,014 | ||
| Accumulated deficit | -96,666,726 | -94,442,098 | ||
| Total stockholders' (deficit) equity | 3,877,385 | 5,888,969 | ||
| Total liabilities and stockholders' (deficit) equity | 8,423,275 | 11,056,707 | ||
Decoy Therapeutics Inc. (DCOY)
Decoy Therapeutics Inc. (DCOY)